Suppr超能文献

L-NAME对严重脓毒性休克白细胞减少患者一氧化氮合酶的抑制作用。

Nitric oxide synthase inhibition by L-NAME in leukocytopenic patients with severe septic shock.

作者信息

Kiehl M G, Ostermann H, Meyer J, Kienast J

机构信息

Department of Internal Medicine, University of Muenster, Germany.

出版信息

Intensive Care Med. 1997 May;23(5):561-6. doi: 10.1007/s001340050373.

Abstract

OBJECTIVES

To investigate the effects of nitric oxide synthase inhibition by NG-nitro-L-arginine methyl ester (L-NAME) on hemodynamics and outcome in leukocytopenic (< 1000/microliter) patients with severe septic shock requiring strong vasopressor support.

DESIGN

Prospective clinical study.

SETTING

Medical intensive care unit.

PATIENTS

10 patients with hematologic malignancies in chemotherapy-induced leukocytopenia with severe septic shock and high-dose vasopressor requirement.

INTERVENTION

Continuous intravenous infusion of L-NAME (0.3 mg/ kg per hour) for a study period of 24 h with prolongation for up to 96 h according to individual requirements.

MEASUREMENTS AND RESULTS

Compared to baseline values, an increase in mean arterial pressure (p = 0.0021), systemic vascular resistance (p = 0.0001), and left ventricular stroke work index (p = 0.023) with a concomitant decrease in vasopressor requirement (p < 0.05) was observed during the first 24 h of L-NAME treatment. Cardiac output data were unchanged during the study period (p = 0.49). L-NAME was tapered off in five patients who again became responsive to vasopressor medication. Two patients survived the episode of septic shock and vasoactive medication was stopped.

CONCLUSIONS

The data demonstrate that inhibition of nitric oxide synthase may be beneficial for the treatment of severe septic shock in leukocytopenic patients as indicated by an increase in systemic vascular resistance, mean arterial pressure, and left ventricular stroke work index.

摘要

目的

研究NG-硝基-L-精氨酸甲酯(L-NAME)抑制一氧化氮合酶对需要强效血管升压药支持的白细胞减少(<1000/微升)的严重脓毒症休克患者血流动力学及预后的影响。

设计

前瞻性临床研究。

地点

内科重症监护病房。

患者

10例血液系统恶性肿瘤患者,化疗引起白细胞减少,伴有严重脓毒症休克且需要大剂量血管升压药。

干预

持续静脉输注L-NAME(0.3毫克/千克每小时),研究期24小时,根据个体需求可延长至96小时。

测量与结果

与基线值相比,在L-NAME治疗的最初24小时内,平均动脉压(p = 0.0021)、全身血管阻力(p = 0.0001)和左心室每搏功指数(p = 0.023)升高,同时血管升压药需求减少(p < 0.05)。研究期间心输出量数据无变化(p = 0.49)。5例患者逐渐减少L-NAME用量后,对血管升压药再次产生反应。2例患者脓毒症休克发作存活,血管活性药物停用。

结论

数据表明,抑制一氧化氮合酶可能有利于治疗白细胞减少患者的严重脓毒症休克,表现为全身血管阻力、平均动脉压和左心室每搏功指数升高。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验